Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamic/Pharmacokinetic Study of SABER-Bupivacaine During Open Inguinal Hernia Repair
2005-000538-19Phase 2Completed
- Sponsor
- DURECT Corporation
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of bupivacaine in postoperative pain, sponsored by DURECT Corporation. Primary endpoints: Sum of Pain Intensity Difference (SPID) Days 1–5, Total Pain Relief (Days 1–5) and 2 more. Started Feb 2005; status: completed.
02
Drugs
bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on 2005-000538-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000538-19.